Biomedica Immunoassays provides internationally recognized, high quality ELISAs for clinical research in the field of cardiovascular and renal diseases as well as bone and mineral disorders. Biomedica’s customers include numerous top ranking scientific institutions worldwide, well-known CROs, and laboratories in the pharmaceutical industry. The company is dedicated in setting the standard for clinical research and provides high quality and fully validated assays with serum-based calibrators and controls. Biomedica has become a world-wide market leader with a continuously growing portfolio which includes ELISAs for FGF23, NT-proBNP, (Big) Endothelin, proANP, Endostatin, oxidized LDL, oLAB, Periostin, Sclerostin, Osteoprotegerin, DKK-1 and FREE soluble RANKL. The majority of Biomedica’s assays are CE marked and ready for use in IVD. Biomedica also offers C4d antibodies for the detection of humoral transplant rejection.
First FGF23 (C-terminal) ELISA, CE marked!
for both serum and plasma samples
High Sensitive FREE soluble RANKL ELISA
Measurable concentrations in healthy subjects
Biomedica offers ELISA kits for the determination of biomarkers of bone metabolism. Our assay portfolio ranges from Osteoprotegerin and a highly sensitive free soluble RANKL assay to biomarkers of the Wnt signaling pathway such as Periostin, Sclerostin and DKK-1 as well as osteocyte derived FGF23.
Our ELISA assays are fully validated to ensure high quality and reproducibility.
Every kit includes five to seven calibrators and one to two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.
Biomedica offers ELISA kits for the determination of biomarkers in cardiovascular disease. Our assay portfolio ranges from natriuretic peptides, such as NT-proBNP and NT-proANP, to the Endothelins including Big ET and ET. Osteoprotegerin, a regulator of bone metabolism has evolved to a biomarker of cardiovascular disease.
Our ELISA assays are fully validated to ensure high quality and reproducibility. Every kit includes five to six calibrators and one to two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.
Biomedica's oxidative stress product line covers biomarkers for risk stratification (OxyStat and MDA-oxidized LDL) and one biomarker to determine the severity of disease (oLAB - anti oxidized LDL autoantibodies).
Our ELISA assays include six calibrators and one to two controls in human serum matrix, thus allowing researchers to collect biologically reliable data.
Nephrology & Transplant
Biomedica offers ELISA kits for the determination of biomarkers in kidney disease. Our assay portfolio ranges from FGF23 (fibroblast growth factor 23) to Endostatin. The C4d antibody complements this product line as marker of humoral transplant rejection.
Our ELISA assays are fully validated to ensure high quality and reproducibility. Every kit includes six or seven calibrators and one or two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.
Biomedica offers ELISA kits for the diagnostic screening of Lyme Borreliosis - Borrelia recombinant IgG ELISA and Borrelia recombinant IgM ELISA. The combination of antigens used in both Borrelia assays detect antibodies directed against the different Borrelia species, pathogenic for humans, including B. burgdorferi senso strictu.
Our Borrelia assays are fully validated ELISAs to ensure high quality and reproducibility of the results. Results are further confirmed by regular participation in external quality control circles. Each kit includes ready to use reagents and can process serum, plasma, and liquor samples.
Glycomics & Other Products
Biomedica is proud to be the exclusive partner of Glycotechnica offering Glycomics - Simplified Glycoanalysis in Europe. This new technology - based on LecChip™ (Lectin microarrays) - enables quick and accurate glycan profiling for any complex glycans, even for mixtures.
Additionally, Biomedica offers the EZ4U, a non-radioactive cell proliferation and cytotoxicity assay, as well as the RFS, reagents for the elimination of rheumatoid factor in serum and plasma.